drugset / Trial / NCT04826107
Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is an open-label, multicenter, phase II study to evaluate the efficacy and safety of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer.
Timeline
- Start
- 2021-08
- Primary completion
- 2024-08
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | 2 mg/kg | — |
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | 2.5 mg/kg | — |
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | 3 mg/kg | — |